{"brief_title": "A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen", "brief_summary": "To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Ampligen", "Zidovudine"], "criteria": "Inclusion Criteria Patients must have: - HIV-1 seropositivity. - Absolute number of T4 cells 100-300 cells/mm3. - Given informed consent. - Zidovudine (AZT) therapy for 6 months prior to study entry. - At least one of the listed HIV-related clinical symptoms or opportunistic infections: - weight loss > 10 percent, unexplained diarrhea, unexplained intermittent fever, oral candidiasis > 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Evidence of AIDS. - Intercurrent acute medical disorder. Concurrent Medication: Excluded: - Chemotherapy for Kaposi's sarcoma (KS). - Aspirin. - Non-steroidal anti-inflammatory drugs. Patients with the following are excluded: - Inability to return for treatment and evaluation for 12 months. - Intercurrent acute medical disorder. - Evidence of AIDS. - Receiving chemotherapy for Kaposi's sarcoma (KS). - Unwilling or unable to give informed consent. Required: - Zidovudine (AZT). Required at least 6 months prior to study entry: - Zidovudine (AZT). Active drug abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Zidovudine", "mesh_term": ["HIV Infections", "Zidovudine", "poly(I).poly(c12,U)", "Poly I-C"], "id": "NCT00002269"}